Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

Exclusion Criteria

• •Diagnosis of Philadelphia chromosome-positive myeloproliferative neoplasm or chronic myeloid leukemia.
• •Concurrent acute leukemia or other active hematologic malignancy.
• •Severe or uncontrolled comorbid condition, including but not limited to significant cardiac or pulmonary disease, decompensated liver disease, or end-stage renal disease.
• •Active uncontrolled bacterial, viral, or fungal infection.
• •Active gastrointestinal disorder associated with significant bleeding or impaired drug absorption.
• •Significant neurologic or psychiatric disorder that may interfere with study participation or compliance.
• •Known hypersensitivity to selinexor or any of its components.
• •Receipt of another investigational agent or participation in another interventional clinical trial within 4 weeks before enrollment.
• •Recent receipt of cytotoxic chemotherapy, radiotherapy, immunotherapy, or other cytoreductive treatment before study entry.
• •History of substance abuse, alcohol dependence, or illicit drug use that may interfere with adherence to study requirements.
• •Another active malignancy requiring systemic treatment.
• •Clinically significant bleeding disorder, severe coagulopathy, or requirement for long-term therapeutic anticoagulation.
• •Receipt of a live vaccine within 30 days before the first dose of study drug, or planned receipt of a live vaccine during the study.
• •Known active infection with human immunodeficiency virus or active viral hepatitis.
• •Estimated life expectancy of less than 12 weeks.
• •Inability to provide informed consent due to cognitive impairment or severe psychiatric illness.
• •Any condition that, in the investigator's judgment, would make the participant unsuitable for participation in this study.